Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)

Authors :: Groot, S. de
Pijl, H.
Charehbili, A.
Ven, S. van de
Smit, V.T.
Meershoek-Klein Kranenbarg, Elma
Laarhoven, H.W.M. van
Hoeven, J.J.M. van der
Nortier, J.W.
Kroep, Judith R.
Groot, S. de
Pijl, H.
Charehbili, A.
Ven, S. van de
Smit, V.T.
Meershoek-Klein Kranenbarg, Elma
Laarhoven, H.W.M. van
Hoeven, J.J.M. van der
Nortier, J.W.
Kroep, Judith R.
Source :: Breast Cancer Research; 1465-542X; 1; 21; 97; ~Breast Cancer Research~~~~~1465-542X~1~21~~97
Publication Year :: 2019
Abstract: Contains fulltext : 207351.pdf (publisher's version ) (Open Access)

Database :: OAIster
Journal :: Breast Cancer Research; 1465-542X; 1; 21; 97; ~Breast Cancer Research~~~~~1465-542X~1~21~~97
Publication Type :: Electronic Resource
Accession number :: edsoai.on1284064463
Document Type :: Electronic Resource

Tools